[E-Daily Starin Choi Hee-jae Reporter] The film “Michael,” which chronicles the life of the “King of Pop” Michael Jackson, has grossed over $1 billion (approximately 1.49 trillion won) at the box office. This marks the first time a biopic has achieved such a feat and sets a new record for the highest-grossing biopic of all time. Poster for the movie “Michael.” (Photo: Universal Pictures) According to the U.S. entertainment media outlet Variety on the 13th (local time), “Michael” has surpassed $1 billion in global box office revenue. Since its release, the film has earned $371.8 million in North America and $629.8 million in international markets, for a total of $1,001.6 million. Among biopics, it has surpassed Christopher Nolan’s “Oppenheimer” (2023, $975 million), which chronicles the life of physicist Julius Robert Oppenheimer, and “Bohemian Rhapsody” (2018, $911 million), which tells the story of the legendary rock band Queen and Freddie Mercury. Director Antoine Fuqua, who helmed “Michael,” said, “This achievement belongs to everyone who came together with the shared goal of honoring one of the greatest artists of all time,” adding, “I sincerely thank audiences around the world who connected with this story across generations and cultures.” Universal Pictures’ animated film “Super Mario Galaxy” ($1.008 billion) was the first film this year to reach the $1 billion mark, with “Michael” being the second. Disney’s “Toy Story 5” is projected to become the third film this year to surpass $1 billion. “Michael” is a film that brings Michael Jackson’s life and music to the screen; it has earned critical acclaim for its stage direction—which feels like a live concert—and its overwhelming sound.
Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
SCL Science(246960)is accelerating its new drug development efforts, spearheaded by vaccines for liver and ovarian cancer. With the goal of submitting an Investigational New Drug (IND) application nex…
“Batoclimab,” a treatment for autoimmune diseases developed by HANALL BIOPHARMA CO.,LTD(009420), has received new drug approval in China. This comes approximately nine years after the company licensed…